相关实验视频

Updated: Jun 9, 2025

Author Spotlight: Exploring Breathing Techniques and Digital Solutions for Enhancing Running Performance
06:26

Author Spotlight: Exploring Breathing Techniques and Digital Solutions for Enhancing Running Performance

Published on: September 27, 2024

386

针对肺高血压的智能手机应用程序:系统搜索和内容评估

Nerea Báez Gutiérrez1, Héctor Rodríguez Ramallo2, Elva María Mendoza-Zambrano3

  • 1Pharmacy Department, Hospital Universitario Virgen Macarena, Seville, Spain.

JMIR mHealth and uHealth
|October 30, 2024
PubMed
概括

肺高血压 (PH) 的移动健康应用程序正在出现,提供可接受的质量,但需要改进. 医疗保健专业人员的参与显著提高了应用程序的质量,强调了临床验证和以患者为中心的设计的必要性.

关键词:
应用程序应用程序应用程序应用程序开发开发应用程序开发慢性病是一种慢性病.临床验证 临床验证电子健康 电子健康评价 评价 评价 评价这种高血压,高血压.移动健康 移动健康 移动健康 移动健康移动应用程序 移动应用程序移动健康应用程序监控 监控 监控 监控 监控 监控肺动脉肺动脉是什么意思肺高血压是一种肺高血压.智能手机的智能手机智能手机的智能手机.系统的搜索系统的搜索

更多相关视频

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.6K
Subjective Refraction Test Using a Smartphone for Vision Screening05:36

Subjective Refraction Test Using a Smartphone for Vision Screening

Published on: October 18, 2024

615

相关概念视频

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
151
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
142
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
129
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
136